Skip to main content

16-02-2017 | Image

Table 1: Clinical efficacy of second generation CAR-T-cell therapy

*In published report. In reported abstract. §Doses unknown. ||PCR is pentostatin 4 mg/m2 day 1, cyclophosphamide 600 mg/m2 day 1, rituximab 375 mg/m2 day 1. Abbreviations: ALL, acute lymphocytic leukaemia; BEAM, BCNU (carmustine) + etoposide + cytarabine + melphalan; B-NHL, B-cell non-Hodgkin lymphoma; CAR, chimeric antigen receptor; CLL, chronic lymphocytic leukaemia; CR, complete response; CVAD, cyclophosphamide + vincristine + doxorubicin + dexamethasone; CY, cyclophosphamide; EPOCH, etoposide + vincristine + doxorubicin + cyclophosphamide + prednisone; FLU, fludarabine; Fred Hutchinson, Fred Hutchinson Cancer Research Center; i.v., intravenous; MSKCC, Memorial Sloan Kettering Cancer Center; NCI, National Cancer Institute; NA, not applicable; ORR, overall response rate; OS, overall survival; PR, partial response; RFS, relapse-free survival; SD, stable disease; UPenn, University of Pennsylvania; VP, etoposide.

Image Credits